Full name
SYMBIO-LAB SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
20.42.Z - Manufacture of cosmetics and toilet preparations
20.53.Z - Manufacture of chemicals and chemical products
21.10.Z - Manufacture of basic pharmaceutical products
46.75.Z - Wholesale trade
46.90.Z - Non-specialized wholesale trade
47.75.Z - Retail sale of cosmetics and toiletries
47.91.Z - Intermediary retail sale, non-specialized
47.99.Z - Retail trade
81.10.Z - Auxiliary activities related to maintaining buildings
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 0 | -0,2 | 0,1 | 184,2 |
EBITDA | 0,1 | -0,1 | 0,2 | 214,6 |
Short time liabilities | 0,4 | 0,4 | 0,5 | 3,6 |
Equity capital | 0,1 | -0,1 | 0,1 | 190,3 |
Operating profit (EBIT) | 0 | -0,2 | 0,1 | 187,8 |
Assets | 0,5 | 0,4 | 0,5 | 38,4 |
Net profit (loss) | 0 | -0,2 | 0,1 | 184,2 |
Cash | 0,2 | 0 | 0,1 | 284,3 |
Net income from sale | 1,7 | 1,6 | 2,3 | 39,7 |
Liabilities and provisions for liabilities | 0,4 | 0,5 | 0,5 | 0,5 |
Working assets | 0,4 | 0,3 | 0,5 | 49,8 |
Depreciation | 0 | 0 | 0 | -4,5 |
% | % | % | p.p. | |
Profitability of capital | 26,9 | 226,2 | 210,7 | -15,5 |
Equity capital to total assets | 20,9 | -19,8 | 13 | 32,8 |
Gross profit margin | 1,8 | -10,4 | 6,2 | 16,6 |
EBITDA Margin | 3,9 | -8,6 | 7 | 15,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 83 | 98 | 73 | -25 |
Current financial liquidity indicator | 1.0881855487823486 | 0.7514944672584534 | 1.0871574878692627 | 0,3 |
Net dept to EBITDA | 0.45454034209251404 | -1.5749942064285278 | 0.846815824508667 | 2,4 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane